Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Efficacy of Primary Total Mesorectal Excision (TME) Surgery Versus Neoadjuvant Chemotherapy Combined With TME Surgery in Low-risk Locally Advanced Rectal Cancer
Sponsor: Sun Yat-sen University
Summary
Comparative analysis of the clinical efficacy between primary Total Mesorectal Excision (TME) surgery and neoadjuvant chemotherapy combined with TME surgery for low-risk locally advanced rectal cancer. Randomly enrolling eligible patients into either the control group receiving neoadjuvant chemotherapy combined with TME surgery or the experimental group receiving primary TME surgery, and subsequently comparing the clinical outcomes of the two groups
Official title: TME vs TME+nCT in Low-risk LARC
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
766
Start Date
2022-07-05
Completion Date
2028-07
Last Updated
2023-08-09
Healthy Volunteers
No
Conditions
Interventions
neoadjuvant chemotherapy plus total mesorectal excision
Neoadjuvant chemotherapy regimen recommended FOLFOX6, XELON, FOLFOX, mFOLFOX for 4-6 courses, and TME surgical treatment after preoperative tumor restaging 1-2 weeks after neoadjuvant chemotherapy.
total mesorectal excision
Standard total mesorectal excision
Locations (6)
Daping Hospital, Amy Medeical Univerisity
Chongqing, Chongqing Municipality, China
Sun yat-sen University, the Sixth Affiliated Hospital
Guangzhou, Guangdong, China
The First Affiliated Hospital of University of South China
Hengyang, Hunan, China
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
The Affiliated Nanchong Central Hospital of North Sichuan Medical College
Nanchong, Sichuan, China